"Coronary Vessel Restoration Therapy with BRS in Stable Angina Long (> 40 mm) Mixed Plaque Lesions"

The aim of single centre study is to evaluate short and long-term clinical, angiographic and imaging outcomes in long (> 40 mm), mixed plaque coronary artery lesions after implantation of bioresorbable scaffold (BRS) or new-generation everolimus-eluting (EE) metallic drug-eluting stent (DES).

Between November 2016 and November 2018 in the Latvian Centre of Cardiology, 33 patients with stable angina included in the prospective, randomized, single blind on-going study for long, calcified coronary artery lesions treated with BRS or new generation EE-DES, 2:1 allocation. First small sample group analysis was reported at six-months clinical follow-up. One in-hospital non-Q MI in each group was recorded (p=0.565). One non-cardiac death in BRS group (p=0.492). One target lesion revascularization in DES group (p=0.162). No scaffold/stent thrombosis or bleeding recorded. First short-term clinical results in BRS group are safe and comparable with current “gold standard” new generation EE-DES.